ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced endometrial cancer: Three-Drug cocktails tested
Disease control OngoingThis study tested three different combinations of chemotherapy and targeted drugs in 349 people with advanced or recurrent endometrial cancer. The goal was to see which combination worked best to stop the cancer from growing or spreading. Participants received one of three treatm…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:48 UTC
-
New drug cocktails aim to stall endometrial Cancer's return
Disease control OngoingThis study tests several drug combinations in women whose endometrial cancer has returned or not responded to treatment. The goal is to see if these combinations can slow or stop cancer growth better than current options. About 288 women are taking part, receiving different drugs…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 813 participants with stage III, IV, or recurrent di…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
New imaging methods could spare women unnecessary surgery for endometrial cancer
Knowledge-focused OngoingThis study looks at whether special scans (PET/CT) and a dye that highlights lymph nodes can find cancer that has spread from the womb in women with high-risk endometrial cancer. About 100 women will get both tests before surgery to see how well they work compared to standard sur…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC
-
New drug triapine tested in uterine cancer before surgery
Knowledge-focused OngoingThis early-phase trial studies how the drug triapine affects uterine serous cancer cells in 12 women scheduled for hysterectomy. Participants receive one dose of triapine before surgery, and researchers compare tumor samples taken before and after the drug to see if it slows canc…
Matched conditions: ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:49 UTC